Elevated serum markers for collagen synthesis in patients with hypertrophic cardiomyopathy and diastolic dysfunction

M Fassbach1, B Schwartzkopff

  • 1Dept. of Cardiology, Angiology and Pneumology, Heinrich-Heine-University Düsseldorf, Moorenstrasse 5, 40225 Düsseldorf, Germany.

Zeitschrift Fur Kardiologie
|May 4, 2005
PubMed

Insights

In hypertrophic cardiomyopathy (HCM), elevated collagen synthesis markers and increased collagenolysis inhibition indicate fibrosis, explaining diastolic dysfunction. This study measured serum markers to understand collagen metabolism in HCM patients.

Area of Science:

  • Cardiovascular Medicine
  • Biochemistry
  • Pathophysiology

Background:

  • Hypertrophic cardiomyopathy (HCM) is a prevalent condition with diverse clinical presentations.
  • Left ventricular hypertrophy and elevated intramyocardial collagen contribute to diastolic dysfunction in HCM.

Purpose of the Study:

  • To investigate the hypothesis of impaired collagenolysis in patients with HCM.
  • To measure serum markers of type-I collagen metabolism.
  • To correlate these markers with echocardiographic parameters of diastolic function.

Main Methods:

  • Serum levels of matrix metalloproteinase-1 (MMP-1), its inhibitor TIMP-1, and collagen type-I markers (PICP, ICTP) were measured in 26 HCM patients and 38 controls.
  • Assays used included ELISA and RIA.
  • Diastolic function was assessed using Doppler echocardiography.

Main Results:

  • Elevated free TIMP-1 and PICP levels were observed in HCM patients compared to controls.
  • Free MMP-1 was significantly lower in HCM patients.
  • The MMP-1/TIMP-1 ratio was reduced in HCM, suggesting inhibited collagenolysis. PICP correlated with diastolic E/A ratio and septal thickness.

Conclusions:

  • Increased serum PICP indicates heightened collagen synthesis in HCM.
  • Elevated TIMP-1 and a reduced MMP-1/TIMP-1 ratio suggest inhibited collagenolysis and collagen accumulation (fibrosis).
  • This collagen accumulation likely explains the passive diastolic dysfunction observed in HCM patients.
Abstract

Related Concept Videos

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...